NASDAQ:ADMP - Adamis Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$4.35 0.00 (0.00 %)
(As of 05/27/2018 04:00 PM ET)
Previous Close$4.35
Today's Range$4.25 - $4.35
52-Week Range$2.35 - $6.45
Volume265,185 shs
Average Volume548,330 shs
Market Capitalization$145.24 million
P/E Ratio-4.83
Dividend YieldN/A
Beta0.36

About Adamis Pharmaceuticals (NASDAQ:ADMP)

Adamis Pharmaceuticals logoAdamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's specialty pharmaceutical product candidates comprise Symjepi (epinephrine) Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis. It also offers dry powder inhaler products consisting of albuterol (APC-2000) for the treatment of bronchospasms; fluticasone (APC-4000) for the treatment of asthma; beclomethasone (APC-1000), a metered dose inhaler product for the asthma; and naloxone injection product candidates (APC-6000) for the treatment of opioid overdose. In addition, the company provides corticosteroids, hormone replacement therapies, hospital outsourcing products, injectables, urological preparations, ophthalmic preparations, topical compounds for pain, and men's and women's health products; and certain veterinary pharmaceutical products for animals. Adamis Pharmaceuticals Corporation is headquartered in San Diego, California.

Receive ADMP News and Ratings via Email

Sign-up to receive the latest news and ratings for ADMP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ADMP
CUSIPN/A
Phone858-997-2400

Debt

Debt-to-Equity Ratio0.07
Current Ratio1.88
Quick Ratio1.57

Price-To-Earnings

Trailing P/E Ratio-4.83
Forward P/E Ratio-5.88
P/E GrowthN/A

Sales & Book Value

Annual Sales$13.07 million
Price / Sales11.11
Cash FlowN/A
Price / CashN/A
Book Value$1.00 per share
Price / Book4.35

Profitability

EPS (Most Recent Fiscal Year)($0.90)
Net Income$-25,530,000.00
Net Margins-207.24%
Return on Equity-71.68%
Return on Assets-56.06%

Miscellaneous

Employees126
Outstanding Shares33,390,000

Adamis Pharmaceuticals (NASDAQ:ADMP) Frequently Asked Questions

What is Adamis Pharmaceuticals' stock symbol?

Adamis Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADMP."

How were Adamis Pharmaceuticals' earnings last quarter?

Adamis Pharmaceuticals Co. (NASDAQ:ADMP) issued its quarterly earnings results on Thursday, May, 10th. The specialty pharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by $0.06. The specialty pharmaceutical company had revenue of $3.18 million for the quarter, compared to the consensus estimate of $3.34 million. Adamis Pharmaceuticals had a negative net margin of 207.24% and a negative return on equity of 71.68%. View Adamis Pharmaceuticals' Earnings History.

When is Adamis Pharmaceuticals' next earnings date?

Adamis Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, August, 13th 2018. View Earnings Estimates for Adamis Pharmaceuticals.

What price target have analysts set for ADMP?

4 brokers have issued 12-month price objectives for Adamis Pharmaceuticals' shares. Their forecasts range from $7.00 to $10.00. On average, they expect Adamis Pharmaceuticals' stock price to reach $7.8750 in the next twelve months. View Analyst Ratings for Adamis Pharmaceuticals.

What are Wall Street analysts saying about Adamis Pharmaceuticals stock?

Here are some recent quotes from research analysts about Adamis Pharmaceuticals stock:
  • 1. Maxim Group analysts commented, "Adamis reported 1Q18 with revenue of $3.2M from the compounding business, up 11.9% sequentially. The company ended the period with a net loss of $7.6M and $10.1M in cash on the balance sheet. Growing revenue in the compounding business should continue to partially offset cash burn and we expect that a partnership for Symjepi to come with an upfront payment that could extend the runway. Partnering discussions are advancing. We have removed the risk cut in our Symjepi model (prior 30%) and made some other minor model, increasing PT to $10, from $5.." (5/11/2018)
  • 2. According to Zacks Investment Research, "Adamis Pharmaceuticals Corporation, formerly Cellegy Pharmaceuticals, Inc., is a specialty pharmaceutical company engaged engages in the research, development, and commercialization of prescription medicines for the treatment of viral infections. Adamis Pharmaceuticals is composed of two wholly owned subsidiaries, Adamis Labs and Adamis Viral Therapies. Adamis Labs is a commercial stage specialty pharmaceutical company targeting high-prescribing physicians in the allergy, respiratory and pediatric medicine market segments. To complement and add to the sales efforts of Adamis Labs, Adamis Viral Therapies is focused on the development of patented, highly-valued proprietary vaccine technology that Adamis believes has the potential to prevent or treat infections such as influenza or chronic hepatitis. Adamis also provides packaging for pharmaceutical and nutraceutical products. The company is headquartered in Del Mar, California. " (3/16/2018)

Who are some of Adamis Pharmaceuticals' key competitors?

Who are Adamis Pharmaceuticals' key executives?

Adamis Pharmaceuticals' management team includes the folowing people:
  • Mr. Richard C. Williams, Chairman and Consultant (Age 74)
  • Dr. Dennis J. Carlo Ph.D., Chief Exec. Officer, Pres and Director (Age 75)
  • Mr. Robert O. Hopkins, Chief Financial Officer, VP of Fin. and Sec. (Age 58)
  • Mr. David J. Marguglio, Chief Bus. Officer, Sr. VP and Director (Age 48)
  • Mr. Robert B. Rothermel, Consultant and Director (Age 74)

Has Adamis Pharmaceuticals been receiving favorable news coverage?

Headlines about ADMP stock have trended somewhat positive on Sunday, Accern Sentiment Analysis reports. The research group ranks the sentiment of news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Adamis Pharmaceuticals earned a coverage optimism score of 0.04 on Accern's scale. They also gave media coverage about the specialty pharmaceutical company an impact score of 48.39 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

Who are Adamis Pharmaceuticals' major shareholders?

Adamis Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Northern Trust Corp (0.42%) and Dimensional Fund Advisors LP (0.21%). View Institutional Ownership Trends for Adamis Pharmaceuticals.

Which major investors are buying Adamis Pharmaceuticals stock?

ADMP stock was bought by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP and Northern Trust Corp. View Insider Buying and Selling for Adamis Pharmaceuticals.

How do I buy shares of Adamis Pharmaceuticals?

Shares of ADMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Adamis Pharmaceuticals' stock price today?

One share of ADMP stock can currently be purchased for approximately $4.35.

How big of a company is Adamis Pharmaceuticals?

Adamis Pharmaceuticals has a market capitalization of $145.24 million and generates $13.07 million in revenue each year. The specialty pharmaceutical company earns $-25,530,000.00 in net income (profit) each year or ($0.90) on an earnings per share basis. Adamis Pharmaceuticals employs 126 workers across the globe.

How can I contact Adamis Pharmaceuticals?

Adamis Pharmaceuticals' mailing address is 11682 EL CAMINO REAL SUITE 300, SAN DIEGO CA, 92130. The specialty pharmaceutical company can be reached via phone at 858-997-2400 or via email at [email protected]


MarketBeat Community Rating for Adamis Pharmaceuticals (ADMP)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  185 (Vote Outperform)
Underperform Votes:  94 (Vote Underperform)
Total Votes:  279
MarketBeat's community ratings are surveys of what our community members think about Adamis Pharmaceuticals and other stocks. Vote "Outperform" if you believe ADMP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADMP will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Adamis Pharmaceuticals (NASDAQ:ADMP) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
4 Wall Street analysts have issued ratings and price targets for Adamis Pharmaceuticals in the last 12 months. Their average twelve-month price target is $7.8750, suggesting that the stock has a possible upside of 81.03%. The high price target for ADMP is $10.00 and the low price target for ADMP is $7.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $7.8750$6.6250$7.3333$10.00
Price Target Upside: 81.03% upside69.87% upside118.91% upside115.05% upside

Adamis Pharmaceuticals (NASDAQ:ADMP) Consensus Price Target History

Price Target History for Adamis Pharmaceuticals (NASDAQ:ADMP)

Adamis Pharmaceuticals (NASDAQ:ADMP) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/14/2018HC WainwrightSet Price TargetBuy$7.00HighView Rating Details
5/11/2018Maxim GroupBoost Price TargetBuy ➝ Buy$5.00 ➝ $10.00LowView Rating Details
3/23/2018B. RileyBoost Price TargetBuy ➝ Buy$6.25 ➝ $7.50LowView Rating Details
2/23/2018Raymond JamesSet Price TargetBuy$7.00HighView Rating Details
(Data available from 5/27/2016 forward)

Earnings

Adamis Pharmaceuticals (NASDAQ:ADMP) Earnings History and Estimates Chart

Earnings by Quarter for Adamis Pharmaceuticals (NASDAQ:ADMP)

Adamis Pharmaceuticals (NASDAQ:ADMP) Earnings Estimates

2018 EPS Consensus Estimate: ($0.67)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.15)($0.15)($0.15)
Q2 20181($0.15)($0.15)($0.15)
Q3 20181($0.19)($0.19)($0.19)
Q4 20181($0.18)($0.18)($0.18)

Adamis Pharmaceuticals (NASDAQ ADMP) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/13/2018        
5/10/2018Q1 2018($0.17)($0.2280)$3.34 million$3.18 millionViewN/AView Earnings Details
3/15/2018Q4 2017($0.24)$2.84 millionViewN/AView Earnings Details
11/14/2017Q3 2017($0.21)$3.39 millionViewN/AView Earnings Details
8/14/2017Q2 2017($0.19)$3.81 millionViewN/AView Earnings Details
5/12/2017Q1 2017($0.21)($0.26)$3.00 million$3.04 millionViewN/AView Earnings Details
11/14/2016Q3 2016($0.48)($0.41)$2.08 millionViewN/AView Earnings Details
8/15/2016Q2($0.37)$1.93 millionViewN/AView Earnings Details
5/13/2016Q1 2016($0.48)ViewN/AView Earnings Details
3/23/2016Q4 2015($0.21)ViewN/AView Earnings Details
11/9/2015Q3 2015($0.24)ViewN/AView Earnings Details
8/7/2015Q2 2015($0.27)ViewN/AView Earnings Details
5/14/2015Q1 2015($0.32)ViewN/AView Earnings Details
11/14/2014Q3 2014($0.20)ViewN/AView Earnings Details
8/13/2014Q2 2014($0.27)ViewN/AView Earnings Details
6/23/2014Q1 2014($0.18)ViewN/AView Earnings Details
2/14/2014Q4 2013($0.82)ViewN/AView Earnings Details
11/13/2013Q3 2013($0.17)ViewN/AView Earnings Details
8/19/2013Q2 2013($2.89)ViewN/AView Earnings Details
2/14/2012Q4 2011($0.19)ViewN/AView Earnings Details
11/21/2011Q3 2011($0.27)ViewN/AView Earnings Details
5/13/2009Q4 2008($0.19)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Adamis Pharmaceuticals (NASDAQ:ADMP) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Adamis Pharmaceuticals (NASDAQ ADMP) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 9.60%
Institutional Ownership Percentage: 10.47%
Insider Trading History for Adamis Pharmaceuticals (NASDAQ:ADMP)
Insider Trading History for Adamis Pharmaceuticals (NASDAQ:ADMP)

Adamis Pharmaceuticals (NASDAQ ADMP) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/2/2016David J MarguglioVPSell700$9.00$6,300.00101,527View SEC Filing  
5/16/2016David J MarguglioSVPSell4,000$8.08$32,320.00102,227View SEC Filing  
5/9/2016David J MarguglioSVPSell4,860$10.00$48,600.00106,227View SEC Filing  
5/4/2016David J MarguglioSVPSell4,860$9.17$44,566.20112,227View SEC Filing  
5/3/2016David J MarguglioSVPSell1,140$9.00$10,260.00117,087View SEC Filing  
4/14/2016David J MarguglioSVPSell12,000$7.52$90,240.00118,227View SEC Filing  
8/14/2015Robert B RothermelDirectorBuy7,000$3.33$23,310.00View SEC Filing  
4/20/2015David J MarguglioSVPSell200$5.00$1,000.00View SEC Filing  
4/14/2015David J MarguglioSVPSell2,200$5.01$11,022.00View SEC Filing  
3/4/2015David J MarguglioSVPSell11,800$7.09$83,662.00View SEC Filing  
3/2/2015David J MarguglioSVPSell7,000$6.45$45,150.00View SEC Filing  
2/13/2015Ahmed Shayan Fazlur RahmanMajor ShareholderSell12,076$6.41$77,407.16View SEC Filing  
2/12/2015Ahmed Shayan Fazlur RahmanMajor ShareholderSell38,000$6.40$243,200.00View SEC Filing  
2/3/2015Ahmed Shayan Fazlur RahmanMajor ShareholderSell30,000$6.75$202,500.00View SEC Filing  
1/5/2015David J MarguglioVPSell7,000$6.18$43,260.00View SEC Filing  
12/30/2014David J MarguglioSVPSell12,228$6.09$74,468.52View SEC Filing  
12/29/2014David J MarguglioVPSell772$6.00$4,632.00View SEC Filing  
12/12/2014David J MarguglioSVPSell4,000$5.18$20,720.00View SEC Filing  
9/2/2014William C DenbyDirectorBuy2,500$5.06$12,650.00View SEC Filing  
8/29/2014Robert B RothermelDirectorBuy5,500$4.03$22,165.00View SEC Filing  
6/2/2014David J MarguglioSVPSell4,000$5.56$22,240.00View SEC Filing  
8/14/2013Ahmed Shayan Fazlur RahmanMajor ShareholderSell7,015$0.57$3,998.55View SEC Filing  
8/7/2013Ahmed Shayan Fazlur RahmanMajor ShareholderSell40,000$0.56$22,400.00View SEC Filing  
8/2/2013Ahmed Shayan Fazlur RahmanMajor ShareholderSell67,960$0.57$38,737.20View SEC Filing  
7/30/2013Ahmed Shayan Fazlur RahmanMajor ShareholderSell10,328$0.56$5,783.68View SEC Filing  
7/26/2013Ahmed Shayan Fazlur RahmanMajor ShareholderSell95,000$0.56$53,200.00View SEC Filing  
7/23/2013Ahmed Shayan Fazlur RahmanMajor ShareholderSell141,224$0.57$80,497.68View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Adamis Pharmaceuticals (NASDAQ ADMP) News Headlines

Source:
DateHeadline
Adamis Pharmaceuticals Co. (ADMP) Expected to Announce Earnings of -$0.18 Per ShareAdamis Pharmaceuticals Co. (ADMP) Expected to Announce Earnings of -$0.18 Per Share
www.americanbankingnews.com - May 27 at 9:22 AM
Options Traders Expect Huge Moves in Adamis Pharmaceuticals (ADMP) StockOptions Traders Expect Huge Moves in Adamis Pharmaceuticals (ADMP) Stock
finance.yahoo.com - May 18 at 10:29 AM
Adamis Pharmaceuticals Co. (ADMP) Given Consensus Recommendation of "Buy" by AnalystsAdamis Pharmaceuticals Co. (ADMP) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - May 18 at 5:27 AM
Adamis Pharmaceuticals: Paging Dr. CarloAdamis Pharmaceuticals: Paging Dr. Carlo
seekingalpha.com - May 15 at 9:42 AM
HC Wainwright Analysts Give Adamis Pharmaceuticals (ADMP) a $7.00 Price TargetHC Wainwright Analysts Give Adamis Pharmaceuticals (ADMP) a $7.00 Price Target
www.americanbankingnews.com - May 14 at 12:43 PM
Adamis Pharmaceuticals Co. (ADMP) Expected to Post Quarterly Sales of $3.74 MillionAdamis Pharmaceuticals Co. (ADMP) Expected to Post Quarterly Sales of $3.74 Million
www.americanbankingnews.com - May 12 at 4:10 AM
Adamis Pharmaceuticals (ADMP) PT Raised to $10.00Adamis Pharmaceuticals (ADMP) PT Raised to $10.00
www.americanbankingnews.com - May 11 at 7:05 PM
Adamis Pharmaceuticals (ADMP) Releases  Earnings Results, Misses Estimates By $0.06 EPSAdamis Pharmaceuticals (ADMP) Releases Earnings Results, Misses Estimates By $0.06 EPS
www.americanbankingnews.com - May 11 at 12:46 PM
Adamis Pharmaceuticals Announces First Quarter 2018 Financial Results and Business UpdateAdamis Pharmaceuticals Announces First Quarter 2018 Financial Results and Business Update
finance.yahoo.com - May 11 at 10:12 AM
Adamis: 1Q Earnings SnapshotAdamis: 1Q Earnings Snapshot
finance.yahoo.com - May 11 at 10:12 AM
Zacks: Analysts Anticipate Adamis Pharmaceuticals Co. (ADMP) Will Post Earnings of -$0.17 Per ShareZacks: Analysts Anticipate Adamis Pharmaceuticals Co. (ADMP) Will Post Earnings of -$0.17 Per Share
www.americanbankingnews.com - May 10 at 11:45 AM
ValuEngine Upgrades Adamis Pharmaceuticals (ADMP) to "Hold"ValuEngine Upgrades Adamis Pharmaceuticals (ADMP) to "Hold"
www.americanbankingnews.com - May 4 at 3:35 PM
Adamis Keeps Us Waiting: April UpdateAdamis Keeps Us Waiting: April Update
seekingalpha.com - April 28 at 9:37 AM
Adamis Pharmaceuticals Corp (ADMP) Expected to Post Quarterly Sales of $3.06 MillionAdamis Pharmaceuticals Corp (ADMP) Expected to Post Quarterly Sales of $3.06 Million
www.americanbankingnews.com - April 24 at 1:50 AM
Pre-Open Movers 04/23: (MDR) (VVC) (HSIC) Higher; (AKRX) (CBI) (AA) Lower (more...)Pre-Open Movers 04/23: (MDR) (VVC) (HSIC) Higher; (AKRX) (CBI) (AA) Lower (more...)
www.streetinsider.com - April 23 at 4:37 PM
Implied Volatility Surging for Adamis Pharmaceuticals (ADMP) Stock OptionsImplied Volatility Surging for Adamis Pharmaceuticals (ADMP) Stock Options
finance.yahoo.com - April 23 at 9:35 AM
Adamis Pharmaceuticals Corp (ADMP) Receives Consensus Rating of "Hold" from AnalystsAdamis Pharmaceuticals Corp (ADMP) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - April 23 at 9:30 AM
Adamis Pharmaceuticals (ADMP) Earns Buy Rating from Analysts at HC WainwrightAdamis Pharmaceuticals (ADMP) Earns Buy Rating from Analysts at HC Wainwright
www.americanbankingnews.com - April 23 at 8:12 AM
 Brokerages Anticipate Adamis Pharmaceuticals Corp (ADMP) Will Announce Earnings of -$0.19 Per Share Brokerages Anticipate Adamis Pharmaceuticals Corp (ADMP) Will Announce Earnings of -$0.19 Per Share
www.americanbankingnews.com - April 22 at 11:20 PM
What Falling Estimates & Price Mean for Adamis Pharmaceuticals (ADMP)What Falling Estimates & Price Mean for Adamis Pharmaceuticals (ADMP)
finance.yahoo.com - April 10 at 9:28 AM
Adamis Pharmaceuticals (ADMP) Downgraded by ValuEngine to SellAdamis Pharmaceuticals (ADMP) Downgraded by ValuEngine to Sell
www.americanbankingnews.com - April 8 at 9:37 AM
-$0.19 Earnings Per Share Expected for Adamis Pharmaceuticals Corp (ADMP) This Quarter-$0.19 Earnings Per Share Expected for Adamis Pharmaceuticals Corp (ADMP) This Quarter
www.americanbankingnews.com - April 6 at 1:20 AM
Adamis: Wait For ItAdamis: Wait For It
seekingalpha.com - April 4 at 4:40 PM
 Adamis Pharmaceuticals Corp (ADMP) Receives Consensus Rating of "Strong Buy" from Analysts Adamis Pharmaceuticals Corp (ADMP) Receives Consensus Rating of "Strong Buy" from Analysts
www.americanbankingnews.com - April 1 at 1:36 AM
Adamis Pharmaceuticals (ADMP) PT Lowered to $6.25 at B.Riley/FBRAdamis Pharmaceuticals (ADMP) PT Lowered to $6.25 at B.Riley/FBR
www.streetinsider.com - March 26 at 10:08 AM
Adamis Pharmaceuticals (ADMP) Price Target Increased to $7.50 by Analysts at B. RileyAdamis Pharmaceuticals (ADMP) Price Target Increased to $7.50 by Analysts at B. Riley
www.americanbankingnews.com - March 23 at 1:08 PM
Adamis Pharmaceuticals: The Latest Update Still Keeps Us Waiting - Seeking AlphaAdamis Pharmaceuticals: The Latest Update Still Keeps Us Waiting - Seeking Alpha
seekingalpha.com - March 21 at 4:58 PM
Adamis Pharmaceuticals (ADMP) Given a $5.00 Price Target at Maxim GroupAdamis Pharmaceuticals (ADMP) Given a $5.00 Price Target at Maxim Group
www.americanbankingnews.com - March 19 at 5:02 PM
Adamis Gains Footing on Citing Goals, AccomplishmentsAdamis Gains Footing on Citing Goals, Accomplishments
www.baystreet.ca - March 17 at 10:11 AM
Zacks Investment Research Lowers Adamis Pharmaceuticals (ADMP) to SellZacks Investment Research Lowers Adamis Pharmaceuticals (ADMP) to Sell
www.americanbankingnews.com - March 16 at 5:38 PM
Adamis Pharmaceuticals Discusses 2017 Highlights and Business Update - GlobeNewswire (press release)Adamis Pharmaceuticals Discusses 2017 Highlights and Business Update - GlobeNewswire (press release)
globenewswire.com - March 16 at 10:03 AM
FY2017 EPS Estimates for Adamis Pharmaceuticals Corp (ADMP) Reduced by AnalystFY2017 EPS Estimates for Adamis Pharmaceuticals Corp (ADMP) Reduced by Analyst
www.americanbankingnews.com - March 16 at 7:34 AM
Research Analysts Issue Forecasts for Adamis Pharmaceuticals Corps FY2022 Earnings (ADMP)Research Analysts Issue Forecasts for Adamis Pharmaceuticals Corp's FY2022 Earnings (ADMP)
www.americanbankingnews.com - March 15 at 3:10 PM
Adamis Pharmaceuticals (ADMP) Price Target Cut to $0.00Adamis Pharmaceuticals (ADMP) Price Target Cut to $0.00
www.americanbankingnews.com - March 14 at 5:30 PM
Adamis Pharmaceuticals Provides Update on Data Presented at the American Academy of Allergy, Asthma and ... - GlobeNewswire (press release)Adamis Pharmaceuticals Provides Update on Data Presented at the American Academy of Allergy, Asthma and ... - GlobeNewswire (press release)
globenewswire.com - March 8 at 10:30 AM
Adamis Pharmaceuticals Announces Publication of a New Human Factors Study Comparing Its Symjepi™ Epinephrine ... - NasdaqAdamis Pharmaceuticals Announces Publication of a New Human Factors Study Comparing Its Symjepi™ Epinephrine ... - Nasdaq
www.nasdaq.com - March 8 at 10:30 AM
Adamis Pharmaceuticals Announces Publication of a New Human Factors Study Comparing Its Symjepi™ Epinephrine Prefilled Syringe to the Market Leading Product in the Annals of Allergy, Asthma and ImmunologyAdamis Pharmaceuticals Announces Publication of a New Human Factors Study Comparing Its Symjepi™ Epinephrine Prefilled Syringe to the Market Leading Product in the Annals of Allergy, Asthma and Immunology
finance.yahoo.com - March 8 at 10:30 AM
Adamis Pharmaceuticals (ADMP) Given a $5.00 Price Target by Maxim Group AnalystsAdamis Pharmaceuticals (ADMP) Given a $5.00 Price Target by Maxim Group Analysts
www.americanbankingnews.com - March 6 at 3:28 PM
Adamis Pharmaceuticals Provides Update on Data Presented at the American Academy of Allergy, Asthma and Immunology (AAAAI) Joint Congress With the World Allergy OrganizationAdamis Pharmaceuticals Provides Update on Data Presented at the American Academy of Allergy, Asthma and Immunology (AAAAI) Joint Congress With the World Allergy Organization
finance.yahoo.com - March 6 at 9:33 AM
 Analysts Expect Adamis Pharmaceuticals Corp (ADMP) Will Announce Quarterly Sales of $4.05 Million Analysts Expect Adamis Pharmaceuticals Corp (ADMP) Will Announce Quarterly Sales of $4.05 Million
www.americanbankingnews.com - March 4 at 2:56 AM
Zacks: Brokerages Anticipate Adamis Pharmaceuticals Corp (ADMP) to Announce -$0.15 EPSZacks: Brokerages Anticipate Adamis Pharmaceuticals Corp (ADMP) to Announce -$0.15 EPS
www.americanbankingnews.com - March 2 at 9:25 PM
Raymond James Financial Analysts Give Adamis Pharmaceuticals (ADMP) a $7.00 Price TargetRaymond James Financial Analysts Give Adamis Pharmaceuticals (ADMP) a $7.00 Price Target
www.americanbankingnews.com - February 24 at 4:26 PM
Adamis Pharmaceuticals (ADMP) Provides Update on Symjepi Commercialization Plans; in Discussions with Two Potential PartnersAdamis Pharmaceuticals (ADMP) Provides Update on Symjepi Commercialization Plans; in Discussions with Two Potential Partners
www.streetinsider.com - February 23 at 4:43 PM
Adamis Pharmaceuticals Updates Symjepi Commercialization PlansAdamis Pharmaceuticals Updates Symjepi Commercialization Plans
finance.yahoo.com - February 23 at 9:28 AM
What Happened To Adamis? - Seeking AlphaWhat Happened To Adamis? - Seeking Alpha
seekingalpha.com - February 18 at 8:33 AM
Adamis Pharmaceuticals Announces FDA Acceptance for Review for the Supplemental New Drug Application of Its ... - GlobeNewswire (press release)Adamis Pharmaceuticals Announces FDA Acceptance for Review for the Supplemental New Drug Application of Its ... - GlobeNewswire (press release)
globenewswire.com - February 14 at 6:37 AM
Zacks: Analysts Anticipate Adamis Pharmaceuticals Corp (ADMP) Will Post Earnings of -$0.15 Per ShareZacks: Analysts Anticipate Adamis Pharmaceuticals Corp (ADMP) Will Post Earnings of -$0.15 Per Share
www.americanbankingnews.com - February 14 at 5:24 AM
Adamis Pharmaceuticals Announces FDA Acceptance for Review for the  Supplemental New Drug Application of Its Low Dose Symjepi Product CandidateAdamis Pharmaceuticals Announces FDA Acceptance for Review for the  Supplemental New Drug Application of Its Low Dose Symjepi Product Candidate
finance.yahoo.com - February 12 at 3:25 PM
Critical Review: Adamis Pharmaceuticals (ADMP) versus Amgen (AMGN)Critical Review: Adamis Pharmaceuticals (ADMP) versus Amgen (AMGN)
www.americanbankingnews.com - February 7 at 1:12 AM
Novartis (NVS) & Adamis Pharmaceuticals (ADMP) Head-To-Head SurveyNovartis (NVS) & Adamis Pharmaceuticals (ADMP) Head-To-Head Survey
www.americanbankingnews.com - February 6 at 11:06 PM

SEC Filings

Adamis Pharmaceuticals (NASDAQ:ADMP) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Adamis Pharmaceuticals (NASDAQ:ADMP) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Adamis Pharmaceuticals (NASDAQ ADMP) Stock Chart for Sunday, May, 27, 2018

Loading chart…

This page was last updated on 5/27/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.